Results 121 to 130 of about 2,896 (157)
Some of the next articles are maybe not open access.
Drugs, 2020
Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based
openaire +2 more sources
Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based
openaire +2 more sources
Zanubrutinib for the treatment of Waldenström Macroglobulinemia
Expert Review of Hematology, 2020Introduction: Waldenström Macroglobulinaemia (WM) is a heterogeneous, incurable condition which often relapses after chemoimmunotherapy. Novel therapies such as Bruton tyrosine-kinase (BTK) inhibitors have shown to be efficacious in treating WM but with an established, significant toxicity profile seen in the first-generation inhibitor Ibrutinib ...
Kenneth J. C. Lim, Constantine S. Tam
openaire +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients ...
openaire +1 more source
CADTH recommends that Brukinsa (zanubrutinib) should not be reimbursed by public drug plans for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. While evidence from 2 clinical trials showed a response in patients treated with Brukinsa, there is uncertainty in how well patients ...
openaire +1 more source
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2023Andrzej Mital, Habte Yimer, Aileen Cohen
exaly
Disseminated Fungal Infection in a Patient Receiving Zanubrutinib
Clinical Case Reports (discontinued), 2023Madalyn Walsh
exaly
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Blood and Lymphatic Cancer: Targets and Therapy, 2023Ali McBride, Nada Alsuhebany
exaly

